reduce basal insulin dose when starting glp-1 receptor agonist Agonists: An Alternative for Rapid-Acting Insulin? GLP1-RA and SGLT2-i: Implementation and

Only one of those is GLP-1

Bifidobacterium infantis produces the postbiotic acetate, and interacts with Akkermansia and Butyricum to promote an ecosystem in the gut that naturally boosts GLP-1

Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020

This Comment highlights emerging evidence and advocates for clinical strategies that prioritize muscle preservation to ensure the long-term success and safety of pharmacological weight management.

Conclusions To conclude, reduced Cmax and delayed tmax of drugs co-administered with GLP1RAs are consistent with the known delayed gastric output by the latter

This article thoroughly traces the developmental milestones of GLP-1 drugs, from their initial discovery to their clinical application, detailing the evolution of diverse GLP-1 medications along with their distinct pharmacological properties